The “NAFLD-Serum” cohort was limited by the absence of ethnic origin information and the few available clinical characteristics, including age, sex, BMI, ApoA1, A2M, haptoglobin, liver function tests, fasting glucose, total cholesterol, and triglycerides. This evidence concerns the gene HP and metabolic dysfunction-associated steatotic liver disease.